⌘K

Home/Filings/4/0001209191-23-016751

4//SEC Filing

Hallam Trevor 4

Accession 0001209191-23-016751

CIK 0001382101other

View on SEC.gov Company Profile

Filed

Mar 6, 7:00 PM ET

Accepted

Mar 7, 4:30 PM ET

Size

17.8 KB

Accession

0001209191-23-016751

Insider Transaction Report

Form 4

Period: 2023-03-03

SUTRO BIOPHARMA, INC.STRO

Chief Science Officer

Transactions

Exercise/Conversion
Common Stock
2023-03-03+9,750→ 93,131 total
Exercise/Conversion
Common Stock
2023-03-03+12,500→ 105,631 total
Tax Payment
Common Stock
2023-03-03$5.79/sh−7,717$44,681→ 97,914 total
Award
Stock Option (right to buy Common Stock)
2023-03-03+50,000→ 50,000 total
Exercise: $5.79Exp: 2033-02-28→ Common Stock (50,000 underlying)
Award
Restricted Stock Unit (RSU)
2023-03-03+40,000→ 40,000 total
Exp: 2027-03-01→ Common Stock (40,000 underlying)
Exercise/Conversion
Restricted Stock Unit (RSU)
2023-03-03−9,750→ 29,250 total
Exp: 2026-03-04→ Common Stock (9,750 underlying)
Exercise/Conversion
Restricted Stock Unit (RSU)
2023-03-03−12,500→ 25,000 total
Exp: 2025-03-05→ Common Stock (12,500 underlying)

Footnotes (6)

[F1]Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
[F2]Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
[F3]The option vests as to 2.0833% of the total shares monthly, beginning on April 1, 2023, with 100% of the total shares vested and exercisable on March 1, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.
[F4]The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date.
[F5]The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date.
[F6]The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

SUTRO BIOPHARMA, INC.

CIK 0001382101

Entity typeother

Related Parties

1

filerCIK 0001326592

Filing Metadata

Form type: 4
Filed: Mar 6, 7:00 PM ET
Accepted: Mar 7, 4:30 PM ET
Size: 17.8 KB

View on SEC.gov